Endocrine and Neuroendocrine Cancers

doi:10.3390/books978-3-0365-5764-9

Download Url(s)

https://mdpi.com/books/pdfview/book/6620

Contributor(s)

Berruti, Alfredo (editor)

Amoroso, Vito (editor)

Fazio, Nicola (editor)

Language

English

Show full item record

Abstract

Endocrine and neuroendocrine tumors originate from endocrine cells but are heterogeneous in terms of clinical presentation, disease outcome, and treatments available. This Special Issue addresses specific aspects of pre-clinical, clinical, and translational research and clinical management of these diseases with the aim of providing novel insights, addressing current unmet needs, and discussing future treatment perspectives.

URI

https://directory.doabooks.org/handle/20.500.12854/96675

Keywords

neuroendocrine neoplasm; neuroendocrine carcinoma; Ki67 labeling index; Ki67 proliferation index; adrenocortical tissues; EMT; epithelial markers; mesenchymal markers; recurrence-free survival; neuroendocrine neoplasms; molecular targeted therapies; mTOR inhibitors; somatostatin analogs; TPH inhibitors; meta-analysis; medullary thyroid cancer; calcitonin; MEN2; gene carriers; adrenocortical cancer; metastatic pheochromocytoma; metastatic paraganglioma; checkpoint inhibitors; avelumab; ipilimumab; nivolumab; pembrolizumab; neuroendocrine tumor; GEP-NET; PET/CT; PRRT; DOTATOC; crcinoid crisis; neuroendocrine tumors; hemodynamic instability; octreotide; neuroendocrine; molecular profiling; targeted therapies; mutation; fusion; ctDNA; anaplastic thyroid carcinoma; chemotherapy; immune checkpoint inhibitors; tumors associated macrophages; radiotherapy; molecular targeted therapy; gastroenteropancreatic neuroendocrine neoplasms; patient-derived xenograft; tumor spheroids; somatostatin receptor-2; near infrared-labelled octreotide analog; management; Delphi; consensus; pancreatic neuroendocrine tumor; everolimus; angiogenesis; circulating cells; biomarkers; n/a